1. Home
  2. STRS vs SGMT Comparison

STRS vs SGMT Comparison

Compare STRS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stratus Properties Inc.

STRS

Stratus Properties Inc.

N/A

Current Price

$29.97

Market Cap

208.3M

Sector

Real Estate

ML Signal

N/A

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$5.45

Market Cap

204.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
STRS
SGMT
Founded
1992
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
208.3M
204.2M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
STRS
SGMT
Price
$29.97
$5.45
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$27.00
AVG Volume (30 Days)
11.5K
845.8K
Earning Date
11-12-2025
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$31,912,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.10
$1.73
52 Week High
$31.35
$11.41

Technical Indicators

Market Signals
Indicator
STRS
SGMT
Relative Strength Index (RSI) 65.14 40.85
Support Level $28.85 $5.02
Resistance Level $31.35 $7.20
Average True Range (ATR) 0.96 0.49
MACD 0.17 -0.01
Stochastic Oscillator 69.60 19.91

Price Performance

Historical Comparison
STRS
SGMT

About STRS Stratus Properties Inc.

Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the acquisition, entitlement, development, management, operation and sale of commercial, multi- and single-family residential real estate properties, located in the Austin Texas area and other select markets in Texas. It operates its business through two segments namely, Real Estate Operations and Leasing Operations. Real Estate Operations segment encompasses activities associated with entitlement, development, and sale of real estate. Leasing Operations segment involves leasing of commercial space at retail and mixed-use properties and residences in multi-family properties that company developed. Majority of revenue is from Real Estate Operations.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: